ACCEPT DECLINE
Change Visitor Type

Portfolio

Oxford BioTherapeutics

Oxford BioTherapeutics is an oncology drug discovery business. By exploiting its proprietary database of human cell-surface proteins, it creates and develops novel targeted oncology therapeutics, with a focus on Antibody Drug Conjugates and Immune Oncology treatments.

26
  • Oxford BioTherapeutics Appoints Chief Medical Officer, ​Abderrahim Fandi


    Read more
  • Oncology research: New opportunities for Menarini and OBT


    Read more

  • News and Views

    The lastest industry news and views
    from our team at Oxford Capital.

    see more
  • Oxford BioTherapeutics receives $10 million capital term loan from Silicon Valley Bank


    Read more
  • $1 Billion Oncology Alliance between Menarini Group & Oxford BioTherapeutics


    Read more
  • Oxford BioTherapeutics Progress Antibody-Drug Conjugate as Second Clinical Development Candidate in $1 Billion Oncology Investment Alliance


    Read more